**Supplementary Data**

**Table 1 - Association between rs7025486 and CHD, MI & diabetes in NPSHII**

|  |  |  |  |
| --- | --- | --- | --- |
| **rs7025486** | **No CHD** | **CHD** | **HR\* (95% CI)** |
| GGGAAAA allele freq(95% CI) | 1358 (56.4)882 (36.7)166 (6.9)0.252(0.240-0.265) | 140 (51.1)115 (42.0)19 (6.9)0.279(0.242-0.319) | 1.13 (0.93-1.36)P=0.21 |
|  | **No MI** | **MI** | **HR\* (95% CI)** |
| GGGAAAA allele freq(95% CI) | 1398 (56.0)927 (37.1)172 (6.9)0.255(0.242-0.267) | 100 (54.6)70 (38.3)13 (7.1)0.262(0.218-0.311) | 1.03 (0.82-1.31)P=0.77 |
|  | **No diabetes** | **Diabetes** | **HR\* (95% CI)** |
| GGGAAAA allele freq(95% CI) | 1374 (55.9)917 (37.3)169 (6.9)0.255(0.243-0.268) | 87 (57.2)53 (34.9)12 (7.9)0.253(0.205-0.306) | 0.95 (0.73-1.12)P=0.70 |

\*hazard ratio per A allele adjusted for age and practice

**Supp Table 1B – Association with CHD in UDACS**

|  |  |  |  |
| --- | --- | --- | --- |
| **rs7025486** | **No CAD** | **CAD** | **OR\* (95% CI)** |
| GGGAAAA allele freq(95% CI) | 217 (60.6)123 (34.4)18 (5.0)0.222(0.192-0.254) | 80 (59.3)46 (34.1)9 (6.7)0.237(0.188-0.292) | 1.09 (0.78-1.52)P=0.606 |

**Supp Table 1C – Association with CHD in Simon Broome FH subjects**

|  |  |  |  |
| --- | --- | --- | --- |
| **rs7025486** | **No CAD** | **CAD** | **OR\* (95% CI)** |
| GGGAAAA allele freq(95% CI) | 128 (59.8)73 (34.1)13 (6.1)0.231(0.192-0.274) | 72 (56.7)49 (38.6)6 (4.7)0.240(0.189-0.298) | 1.08 (0.72-1.65)P=0.701 |

**Supp Table 1D – Association with CHD in CABG vs. NPHSII controls**

|  |  |  |  |
| --- | --- | --- | --- |
| **rs7025486** | **NPHSII controls** | **CABG** | **OR (95% CI)** |
| GGGAAAA allele freq(95% CI) | 1358 (56.4)882 (36.7)166 (6.9)0.252(0.240-0.265) | 165 (49.7)139 (41.9)28 (8.4)0.294(0.259-0.330) | 1.23 (1.03-1.46)P=0.024 |

**Supp Table 1E – Association with CHD in HIFMECH**

|  |  |  |  |
| --- | --- | --- | --- |
|  | **North** | **South** | **N+S** |
| rs7025486 | **Controls** | **Cases** | **Controls** | **Cases** | **Controls** | **Cases** |
| GGGAAAA allele freq(95% CI) | 127 (52.5)98 (40.5)17 (7.0)0.273(0.234-0.315) | 110 (48.7)100 (44.3)16 (7.1)0.292(0.250-0.336) | 191 (61.2)105 (33.7)16 (5.1)0.220(0.188-0.254) | 177 (60.6)100 (34.3)15 (5.1)0.223(0.189-0.259) | 318 (57.4)203 (36.6)33 (6.0)0.243(0.218-0.269) | 287 (55.4)200 (38.6)31 (6.0)0.253(0.227-0.281) |
| Odds ratio\*(95% CI) | 1.34(0.94-1.91)P=0.101 | 1.07 (0.81-1.41)P=0.653 | 1.17 (0.94-1.45)P=0.167 |

**Supp Table 2A Association between rs7025486 and biomarkers in NPSHII**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | GG N=1498 | GA N=997 | AA N=185 | Bx (se) | P value |
| Cholesterol | 5.74 (1.00) | 5.75 (1.01) | 5.74 (1.15) | 0.005 (0.032) | 0.877 |
| TG\* | 1.80 (0.94) | 1.80 (0.95) | 1.80 (1.06) | 0.002 (0.016) | 0.902 |
| HDL\* | 0.80 (0.24) | 0.80 (0.24) | 0.77 (0.26) | -0.014 (0.011) | 0.174 |
| LDL | 4.01 (0.94) | 3.98 (0.97) | 4.05 (1.03) | 0.003 (0.037) | 0.941 |
| ApoA | 1.64 (0.32) | 1.63 (0.31) | 1.61 (0.32) | -0.020 (0.010) | 0.054 |
| ApoB\* | 0.86 (0.24) | 0.87 (0.24) | 0.86 (0.25) | 0.005 (0.009) | 0.558 |
| Fibrinogen\*  | 2.68 (0.52) | 2.75 (0.51) | 2.74 (0.48) | 0.018 (0.006) | 0.002 |
| CRP\* | 2.53 (2.45) | 2.52 (2.53) | 2.53 (2.88) | 0.007 (0.034) | 0.836 |
| Factor VIIc\* | 105.4 (29.2) | 106.2 (27.6) | 104.6 (26.6) | 0.002 (0.008) | 0.791 |
| Factor VIIa\* | 1.97 (1.17) | 2.05 (1.16) | 2.11 (1.28) | 0.021 (0.031) | 0.493 |
| Factor VIIag\* | 125.2 (34.3) | 127.1 (34.9) | 121.2 (32.6) | -0.003 (0.008) | 0.673 |
| Factor IXp\* | 202.8 (63.0) | 198.8 (59.1) | 205.2 (62.6) | -0.004 (0.017) | 0.791 |
| Factor Xp\* | 77.6 (26.1) | 76.2 (30.8) | 83.0 (27.4) | -0.004 (0.021) | 0.832 |
| Factor XIIa\* | 1.79 (0.91) | 1.79 (0.93) | 1.78 (0.89) | 0.015 (0.016) | 0.324 |
| F1.2\* | 0.71 (0.29) | 0.70 (0.28) | 0.71 (0.26) | -0.008 (0.012) | 0.535 |
| FPA\* | 1.33 (0.93) | 1.29 (0.84) | 1.42 (1.21) | -0.001 (0.021) | 0.977 |

xCoefficient per A allele adjusted for age and practice

**Suppl Table 2B - Association between rs7025486 and biomarkers in UDACS**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | GG N=200 | GA N=122 | AA N=19 | Bx (se) | P value |
| Cholesterol | 5.03 (1.08) | 5.08 (1.09) | 5.13 (1.33) | 0.062 (0.080) | 0.441 |
| HDL\* | 1.27 (0.39) | 1.28 (0.34) | 1.28 (0.42) | 0.013 (0.021) | 0.532 |
| LDL\*\* | 2.63 (0.92) | 2.72 (0.95) | 2.70 (0.97) | 0.021 (0.022) | 0.325 |
| TG\* | 1.90 (1.07) | 2.03 (1.17) | 1.89 (0.83) | 0.035 (0.042) | 0.395 |
| CRP\* | 1.81 (1.51) | 1.68 (1.42) | 1.40 (1.21) | -0.098 (0.065) | 0.129 |
| Il-6\* | 3.49 (2.56) | 3.57 (2.69) | 3.50 (2.16) | 0.018 (0.056) | 0.749 |

\*log transformed for analysis. Means are geometric

**Suppl Table2C – Association with Biomarkers in Simon Broome FH subjects**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | GG N=200 | GA N=122 | AA N=19 | Bx (se) | P value |
| Pre-treatmentCholesterol\* | 10.12 (1.89)N=144 | 10.22 (2.11)N=93 | 9.69 (1.78)N=16 | -0.006 (0.019) | 0.742 |
| Cholesterol\* | 6.67 (1.32) | 6.56 (1.33) | 6.68 (1.43) | -0.008 (0.017) | 0.625 |
| TG\* | 1.28 (0.57) | 1.36 (0.63) | 1.31 (0.61) | 0.034 (0.040) | 0.400 |
| HDL\* | 1.35 (0.37) | 1.32 (0.35) | 1.36 (0.32) | -0.013 (0.022) | 0.575 |
| LDL\* | 4.55 (1.28) | 4.42 (1.28) | 4.57 (1.35) | -0.015 (0.025) | 0.535 |
| ApoA\* | 1.37 (0.33) | 1.37 (0.32) | 1.36 (0.25) | -0.001 (0.020) | 0.981 |
| ApoB\* | 1.27 (0.34) | 1.24 (0.37) | 1.29 (0.41) | -0.010 (0.025) | 0.697 |
| Fibrinogen\*  | 2.89 (0.89) | 2.85 (0.96) | 2.89 (0.59) | -0.009 (0.026) | 0.744 |
| CRP\* | 1.32 (1.53) | 1.32 (1.60) | 0.91 (0.77) | -0.085 (0.107) | 0.429 |
| PAI\* | 8.60 (7.02) | 9.78 (6.72) | 8.50 (6.08) | 0.065 (0.067) | 0.350 |
| Il-6\* | 1.81 (1.22) | 1.87 (1.39) | 1.33 (0.93) | -0.057 (0.059) | 0.336 |
| PON\* | 76.1 (69.0) | 71.5 (56.9) | 66.7 (54.8) | -0.065 (0.080) | 0.414 |
| ICAM\* | 300.6 (93.5) | 298.5 (115.2) | 274.7 (116.7) | -0.026 (0.031) | 0.405 |
| Adiponectin\*\* | 11.63 (8.62) | 9.33 (7.24) | 10.55 (9.37) | -0.232 (0.109) | 0.034 |

**Supp Table2D - Association with lipids and haemostatic and inflammatory markers in HIFMECH**

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | **Controls** | **Cases** |
|  | rs7025486 | **North** | **South** | **Combined** | **North** | **South** | **Combined** |
| **Cholesterol** | GGGAAAB (se)**P value** | 5.66 (0.89) 1155.78 (1.12) 935.71 (1.01) 170.076 (0.104)0.466 | 5.46 (0.88) 1905.30 (1.08) 1055.34 (0.70) 16-0.117 (0.091)0.197 | 5.53 (0.89) 3055.53 (1.12) 1985.53 (0.88) 33-0.031 (0.068)0.648 | 5.77 (1.25) 1035.60 (1.21) 925.70 (0.99) 13-0.090 (0.139)0.515 | 5.26 (1.08) 1705.05 (1.20) 954.97 (0.91) 14-0.169 (0.114)0.138 | 5.45 (1.17) 2735.32 (1.23) 1875.32 (1.01) 27-0.134 (0.088)0.128 |
| **TG1** | GGGAAAB (se)**P value** | 1.51 (0.60) 1151.50 (0.57) 931.62 (0.78) 170.016 (0.042)0.695 | 1.39 (0.61) 1901.40 (0.60) 1051.50 (0.62) 160.017 (0.042)0.685 | 1.43 (0.61) 3051.44 (0.59) 1981.56 (0.69) 330.017 (0.030)0.564 | 2.06 (0.84) 1031.87 (0.78) 922.12 (0.88) 13-0.044 (0.047)0.353 | 1.79 (0.68) 1701.73 (0.76) 952.08 (0.77) 140.007 (0.041)0.858 | 1.89 (0.75) 2731.80 (0.77) 1872.10 (0.81) 27-0.015 (0.031)0.618 |
| **APOB2** | GGGAAAB (se)**P value** | 96.9 (20.4) 11599.9 (26.0) 9396.5 (24.6) 170.069 (0.120)0.568 | 95.5 (19.2) 19092.1 (23.3) 10594.6 (11.6) 16-0.112 (0.101)0.265 | 96.0 (19.6) 30595.7 (24.8) 19895.6 (19.1) 33-0.035 (0.077)0.649 | 110.2 (29.4) 103105.1 (26.7) 92114.9 (26.7) 13-0.061 (0.154)0.692 | 97.4 (22.7) 17094.7 (22.4) 9594.8 (19.4) 14-0.102 (0.117)0.384 | 102.1 (26.0) 27399.8 (25.0) 187104.3 (24.7) 27-0.084 (0.094)0.374 |
| **IL-61** | GGGAAAB (se)**P value** | 1.26 (0.66) 1101.28 (0.83) 911.34 (0.65) 170.024 (0.061)0.692 | 1.19 (0.87) 1191.19 (0.65) 651.83 (1.32) 100.102 (0.083)0.218 | 1.22 (0.78) 2291.24 (0.75) 1561.50 (0.89) 270.058 (0.050)0.247 | 1.72 (1.20) 971.70 (1.16) 832.52 (1.10) 130.109 (0.078)0.161 | 2.28 (1.53) 962.05 (1.36) 712.77 (1.41) 10-0.006 (0.083)0.939 | 1.98 (1.38) 1931.85 (1.26) 1542.62 (1.21) 230.054 (0.057)0.342 |
| **CRP1** | GGGAAAB (se)**P value** | 0.92 (1.26) 1160.86 (1.19) 921.12 (1.38) 160.017 (0.146)0.906 | 1.61 (1.50) 1891.41 (1.15) 1051.91 (1.87) 16-0.041 (0.086)0.636 | 1.30 (1.50) 3051.12 (1.28) 1971.46 (1.65) 32-0.015 (0.080)0.852 | 2.28 (2.90) 1061.79 (2.48) 942.40 (3.84) 14-0.099 (0.150)0.512 | 2.43 (2.30) 1702.16 (2.05) 953.01 (2.99) 14-0.008 (0.097)0.935 | 2.37 (2.56) 2761.97 (2.33) 1892.69 (3.53) 28-0.049 (0.086)0.567 |
| **Fibrinogen2** | GGGAAAB(se)**P value** | 3.45 (0.74) 1133.36 (0.67) 913.55 (0.50) 17-0.041 (0.200)0.837 | 3.42 (0.71) 1823.36 (0.65) 1003.39 (0.74) 15-0.147 (0.182)0.421 | 3.43 (0.72) 2953.36 (0.66) 1913.47 (0.62) 32-0.096 (0.134)0.475 | 3.85 (0.84) 1053.68 (0.77) 883.79 (0.85) 13-0.246 (0.238)0.301 | 3.77 (0.96) 1673.48 (1.00) 933.64 (1.03) 14-0.453 (0.264)0.087 | 3.80 (0.91) 2723.58 (0.91) 1813.71 (0.94) 27-0.358 (0.181)0.048 |

Means (standard deviations)

**Supp Table 3 – Interaction between rs7025486 & rs10757274 change to A and G**

|  |  |  |  |
| --- | --- | --- | --- |
| rs107572749p21 | rs7025486*DAB2IP* | Number subjects/Number cases (% CHD) | OR (95% CI) |
| GG | GG | 381/27 (7.1) | 1.00 |
| GG | GA | 281/25 (8.9) | 1.25 (0.72-2.17) |
| GG | AA | 54/4 (7.4) | 0.99 (0.34-2.84) |
| GA | GG | 737/66 (9.0) | 1.19 (0.76-1.87) |
| GA | GA | 477/60 (12.6) | 1.81 (1.15-2.87) |
| GA | AA | 80/9 (11.3) | 1.68 (0.78-3.60) |
| AA | GG | 346/41 (11.9) | 1.74 (1.07-2.85) |
| AA | GA | 224/29 (13.0) | 1.85 (1.08-3.14) |
| AA | AA | 46/6 (13.0) | 1.42 (0.54-3.76) |
| Interaction p value |  | P=0.74 |

**For rs7025486 G= Non risk allele, A= risk allele and for rs10757274 G= Non risk allele, A = risk allele)**

**Supplementary Figure 1 - Combined study results for DAB2IP and loge fibrinogen (additive effect, fixed effects model).**



Combined effect 0.009 (-0.001, 0.020) p=0.077

**Supplementary Figure 2 - Combined study results for DAB2IP and loge CRP (additive effect, fixed effects model).**



Overall effect -0.022 (-0.073-0.028) p=0.38

**Supplementary Fig 3 - Combined study results for DAB2IP and loge IL6 (additive effect, fixed effects model).**



Combined effect 0.022 (-0.032 to 0.076) p=0.432

**Age adjusted telomere length (95% CI) by DAB2IP genotype**

Telomere length is adjusted to age 56. P values are for an additive model.

